The establishment and operational activities of a new partnership between the University of Perugia and Bios-Therapy, Physiological Systems for Health S.p.A., under the name UNIBIOS.
The initiative was conceived to investigate the applicability of modern technologies in the life sciences, moving from a reductionist approach to one of complexity.
This new approach to research and education will facilitate the development of sustainable healthcare in the medium to long term, from both economic and environmental perspective, addressing new requirements such as ONE HEALTH and HTA (Health Technology Assessment).

UNIBIOS was created in November 2024 as an innovative public-private partnership between the University of Perugia, represented by its rector, Professor Maurizio Oliviero, and Bios-Therapy, Physiological Systems for Health S.p.A., represented by Valentino Mercati. The partnership was formed with the above objectives in mind.

All 14 university departments are expected to be involved, while Bios-Therapy will provide its expertise to develop and implement new life sciences technologies, with the aim of promoting the medium- to long-term sustainable development of healthcare.

Founded as a spin-off of the Aboca Group, Bios-Therapy is now a leader in omic sciences as applied to 'new therapeutic processes', particularly physiological processes that complement and/or assist pharmacological treatments.

This Framework Agreement was subsequently followed by an Executive Agreement between the Department of Medicine at the University of Perugia, represented by its Director, Prof. Vincenzo Nicola Talesa, and UNIBIOS, on 20 March 2025. The agreement established the UNIBIOS organisational headquarters and the Multidisciplinary Study Group (MSG), who are working on the subjects in question, building on the success of two clinical trials conducted by the University of Perugia.

These were led by Prof. Patrizia Mecocci in the field of mild cognitive impairment and by Prof. Auro Caraffa in the field of knee osteoarthritis.

These innovative technologies form part of the new approach in European legislation, as set out in the COUNCIL RESOLUTION of 7 May 1985 on a new approach to technical harmonisation and standards (85/C 136/01). The clinical application of these technologies covers the following aspects:

- Bioactive substances, self-assembled by natural intelligence
- The definition of a physiological activity inherent to the entire human metabolism
- Longitudinal clinical trials (N = 1) specific to advanced medicine in personalised therapy

These new technological fields will be supported by generative Artificial Intelligence.

UNIBIOS is therefore a new partnership whose objective is to provide the social and healthcare sectors with long-awaited solutions which reduce the financial burden and imbalance in the risk-benefit ratio of products with a pharmacological effect.

Given the unusual nature of the project, the entire UNIBIOS organisation is available to answer any questions the press may wish to ask.